Immunosuppressant and cytotoxic drugs: Unapproved uses or indications

Clinics in Dermatology

Volumn 18, Issue 1, 2000, Pages 95-101

  Abel, Elizabeth A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; ALKYLATING AGENT; ANTIMETABOLITE; ANTIMITOTIC AGENT; AZATHIOPRINE; BIOLOGICAL RESPONSE MODIFIER; BLEOMYCIN; CYTOTOXIC AGENT; IMMUNOSUPPRESSIVE AGENT; INTERFERON; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PURINE DERIVATIVE;

BASAL CELL CARCINOMA; DERMATITIS; DRUG ACTIVITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION;

ALKYLATING AGENTS; ANTIMETABOLITES; ANTINEOPLASTIC AGENTS; BIOLOGICAL RESPONSE MODIFIERS; DERMATOLOGIC AGENTS; DRUG APPROVAL; DRUG UTILIZATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SKIN DISEASES; SKIN NEOPLASMS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0033984705     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(99)00098-X     Document Type: Review

References (54)

1. McDonald CJ, editor. Immunomodulatory and cytotoxic agents in dermatology. New York: Marcel Dekker, 1997.
2. Callen J.P. Immunosuppressive and cytotoxic drugs in dermatology. Dermatol Ther. 5:1998;22-33.
3. Dutz J.P., Ho V.C. Immunosuppressive agents in dermatology. Dermatol Clin. 16:1998;235-247.
4. Orenberg E.K., Miller B.H., Greenway H.T., et al. The effect of intralesional 5-fluorouracil therapeutic implant (MPI 5003) for treatment of basal cell carcinoma. J Am Acad Dermatol. 27:1992;723-728.
5. Huilgol S.C., Black M.M. Management of the immunobullous disorders II. Pemphigus . Clin Exp Dermatol. 20:1995;283-293.
6. Knowles S.R., Gupta A.K., Shear N.H., et al. Azathioprine hypersensitivity-like reactions A case report and a review of the literature . Clin Exp Dermatol. 20:1995;353-356.
7. Greiner D., Olsen E.A., Petroni G. Pentostatin (2′deoxycoformycin) in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol. 36:1997;950-955.
8. Snow J.L., Gibson L.E. A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients. J Am Acad Dermatol. 32:1995;114-116.
9. Zackheim H.S., Maibach H.I. Treatment of psoriasis with 6-thioguanine. Australas J Dermatol. 29:1988;163-167.
10. Zackheim H.S., Glogau R.G., Fisher D.A. 6-Thioguanine treatment of psoriasis Experience in 81 patients . J Am Acad Dermatol. 30:1994;452-458.
11. Silvis N.G. Pulse dosing of thioguanine in recalcitrant psoriasis. Arch Dermatol. 135:1999;433-437.
12. Yarbro J.W. Mechanism of action of hydroxyurea. Semin Oncol. 19:1991;1-10.
13. Boyd A.S., Neldner K.H. Hydroxyurea therapy. J Am Acad Dermatol. 25:1991;518-524.
14. Daoud M.S., Gibson L.E., Pittelkow M.R. Hydroxyurea dermopathy A unique lichenoid eruption complicating long-term therapy with hydroxyurea . J Am Acad Dermatol. 36:1997;178-182.
15. Jeffes E.W. III, Weinstein G.D. Methotrexate and other chemotherapeutic agents used to treat psoriasis. Dermatol Clin. 13:1995;875-890.
16. Weinstein G., Jeffes E., McCullough J.L., et al. Cytotoxic and immunologic effects of methotrexate in psoriasis. J Invest Dermatol. 95:1990;49S-52S.
17. Jeffes E.W.B., McCollough J.L., Pittelkow M.R., et al. Methotrexate therapy of psoriasis Differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate . J Invest Dermatol. 104:1995;183-188.
18. Zieglschmid-Adams M.E., Pandya A.G., Cohen S.B., et al. Treatment of dermatomyositis with methotrexate. J Am Acad Dermatol. 32:1995;754-757.
19. Albert M.R., Mackool B.T. Pityriasis rubra pilaris. Int J Dermatol. 38:1999;1-11.
20. Clayton B.D., Jorizzo J.L., Hitchcock M.G., et al. Adult pityriasis rubra pilaris A 10-year case series . J Am Acad Dermatol. 36:1997;959-964.
21. Smith T.J., Bystryn J.C. Methotrexate as an adjuvant treatment for pemphigus vulgaris. Arch Dermatol. 135:1999;1275-1276.
22. Heilborn J.D., Stahle-Backdfahl M., Albertioni F., et al. Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid. J Am Acad Dermatol. 40:1999;741-749.
23. Silverman Kitchin J.E., Keltz Pomeranz M., Pak G., et al. Rediscovering mycophenolic acid A review of its mechanism, side effects, and potential uses . J Am Acad Dermatol. 37:1997;445-449.
24. Nousari H.C., Sragovich A., Kimyai-Asadi A., et al. Mycophenolate mofetil in autoimmune and inflammatory skin disorders. J Am Acad Dermatol. 40:1999;265-268.
25. Enk A.H., Knop J. Mycophenolate is effective in the treatment of pemphigus vulgaris. Arch Dermatol. 135:1999;54-56.
26. Hoppe R., Wood G., Abel E.A. Mycosis fungoides and the Sezary syndrome Pathology, staging and treatment . Curr Probl Cancer. 14:1990;295-371.
27. Mills J.A. Systemic lupus erythematosus. N Engl J Med. 330:1994;1871-1879.
28. Fleischli M.E., Valek R.H., Pandya A.G. Pulse intravenous cyclophosphamide therapy in pemphigus. Arch Dermatol. 135:1999;57-61.
29. Burruss J.B., Farmer E.R., Callen J.P. Chlorambucil is an effective corticosteroid-sparing agent for recalcitrant pyoderma gangrenosum. J Am Acad Dermatol. 35:1996;720-724.
30. Winkleman R., Diaz-Perez J., Buechner S. The treatment of Sézary syndrome. J Am Acad Dermatol. 10:1984;1000-1004.
31. James M.P., Collier P.M., Aherne W., et al. Histologic, pharmacologic, and immunocytochemical effects of injection of bleomycin into viral warts. J Am Acad Dermatol. 28:1993;933-937.
32. Cunningham B.B., Kirchmann T.T., Woodley D. Colchicine for epidermolysis bullosa acquisita. J Am Acad Dermatol. 34:1996;781-784.
33. Mangelsdorf H.C., White W.L., Jorizzo J.L. Behcet's disease Report of twenty-five patients from the United States with prominent mucocutaneous involvement . J Am Acad Dermatol. 34:1996;745-750.
34. Hurd D.S., Conte E.T. Practical uses of the interferons in dermatology. Int J Dermatol. 37:1998;881-896.
35. Gross G., Roussaki A., Schopf E., et al. Successful treatment of condylomata acuminata and bowenoid papulosis with subcutaneous injections of low-dose recombinant interferon-alpha. Arch Dermatol. 122:1986;749-750.
36. Gottlieb SL, Gilleaudeau P, Johnson R, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB 389 IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995;1:442-7.
37. Koo J., Lee J. Cyclosporine. What clinicians need to know. Dermatol Clin. 13:1995;897-907.
38. Rosenbach A., Lowe N.J. Pityriasis rubra pilaris and cyclosporine. Arch Dermatol. 129:1992;1346-1348.
39. Berth-Jones J., Finlay A.Y., Zaki I., et al. Cyclosporine in severe childhood atopic dermatitis A multicenter study . J Am Acad Dermatol. 34:1996;1016-1021.
40. Fullerton S.H., Abel E.A., Getz K., et al. Cyclosporine treatment of severe recalcitrant pyoderma gangrenosum in a patient with Takayasu's arteritis. Arch Dermatol. 127:1991;1731-1732.
41. Ghate J.V., Jorizzo J.L. Behcet's disease and complex aphthosis. J Am Acad Dermatol. 40:1999;1-18.
42. Gupta A.K., Ellis C.N., Cooper K.D., et al. Oral cyclosporine for the treatment of alopecia areata A clinical and immunohistochemical analysis . J Am Acad Dermatol. 22:1990;242-250.
43. Lebwohl M., Ellis C., Gottlieb A., et al. Cyclosporine consensus conference With emphasis on the treatment of psoriasis . J Am Acad Dermatol. 39:1998;464-475.
44. Gupta A.K., et al. The use of cyclosporine to treat cutaneous diseases. Dermatol Ther. 5:1998;64-73.
45. Gilhar A., Pillar T., Etzioni A. Topical cyclosporine in male pattern alopecia. J Am Acad Dermatol. 22:1990;251-253.
46. Lawrence I.D. Tacrolimus (FK506) Experience in dermatology . Dermatol Ther. 5:1998;74-84.
47. Ruzicka T., Bieber T., Schöph E., et al. A short-term trial of tacrolimus (FK506) ointment for atopic dermatitis. N Engl J Med. 337:1997;816-821.
48. Lauerma A.I., Maibach H.I., Granlund H., et al. Inhibition of contact allergy reactions by topical FK 506. Lancet. 340:1992;556.
49. Systemic tacrolimus (FK506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. Arch Dermatol. 132:1996;419-423.
50. Beutner KR, Spruance SL, Hougham A, et al. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 98;38:230-9.
51. Tosti A., Guidetti S., Bardazzi F., et al. Long-term results of topical immunotherapy in children with alopecia totalis or alopecia universalis. J Am Acad Dermatol. 35:1996;199-201.
52. Hoting E., Boehm A. Therapy of alopecia areata with diphencyprone. Br J Dermatol. 127:1992;625-629.
53. Susser W.S., Whitaker-Worth D.L., Grant-Kels J.M. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol. 40:1999;367-398.
54. Alexander J. Chemotherapy Uses and safety considerations . Dermatol Nurs. 3:1991;107-109.